Tuberculosis in liver transplant recipients: A systematic review and meta-analysis of individual patient data

Liver Transplantation

Volumn 15, Issue 8, 2009, Pages 894-906

  Holty, Jon Erik C ^a,b   Gould, Michael K ^a,b,c   Meinke, Laura ^d   Keeffe, Emmet B ^b   Ruoss, Stephen J ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETHAMBUTOL; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; GEOGRAPHIC DISTRIBUTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HYPERACUTE GRAFT REJECTION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; META ANALYSIS; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 69949097461     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21709     Document Type: Article

References (145)

1. Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2006. Natl Vital Stat Rep 2006;54:1-54.
2. Centers for Disease Control and Prevention. Death rates for 72 selected causes, United States, 1993, 1994, 1995, 1996, 1997, and 1998. Available at: http://www.cdc.gov.laneproxy.stanford.edu/nchs/datawh/statab/unpubd/ mortabs/gmwk250.htm. Accessed August 2007.
3. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886-897.
4. Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, Dodson SF, et al. Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year followup. Transplant Proc 2001;22:1482-1483.
5. Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 2000;4: 657-673.
6. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999;282:677-686.
7. Fuchs GF. Criteria for prophylaxis in active tuberculosis. Arch Environ Health 1965;10:937-941.
8. Sutherland I, Svandova E, Radhakrishna S. Alternative models for the development of tuberculosis disease following infection with tubercle bacilli. Bull Int Union Tuberc 1976;51:171-179.
9. Rao VK, Iademarco EP, Fraser VJ, Kollef MH. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 1998;114:1244-1252.
10. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27: 1266-1277.
11. Montejo M, Valdivielso A, Suárez MJ, Testillano M, Bustamante J, Gastaca M, et al. Infection after orthotopic liver transplantation: analysis of the first 120 consecutive cases. Rev Clin Esp 2000;200:245-251.
12. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. Veterans Administration Cooperative Study XII. Chest 1978;73:44-48.
13. Braslavsky G, Jacob N, Maiolo E, Trigo P, Aziz H, Imventarza O. Tuberculosis in liver transplant patients. Transplant Proc 1999;31:3063-3063.
14. Lu W, Wai CT, Da Costa M, Tambyah PA, Prabhakaran K, Lee KH. Tuberculosis post-liver transplantation: a rare but complicated disease. Ann Acad Med Singapore 2005; 34:213-215.
15. Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, Rimola A. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002;74:1381-1386.
16. Higgins RSD, Kusne S, Reyes J, Yousem S, Gordon R, Van Thiel D, et al. Mycobacterium tuberculosis after liver transplantation: management and guidelines for prevention. Clin Transplant 1992;6:81-90.
17. Torre-Cisneros J, de la Mata M, Rufian S, Villanueva Marcos JL, Gutierrez Aroca J, Casal M, et al. Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 1995;60:1054-1055.
18. Grauhan O, Lohmann R, Lemmens P, Schattenfroh N, Jonas S, Keck H, et al. Mycobacterial infection after liver transplantation. Langenbecks Arch Chir 1995;380:171-175.
19. Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2003;52(RR11):1-77.
20. Chan ACY, Lo CM, Ng KKC, Chan SC, Fan ST. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int 2007;27:81-85.
21. Hsu MS, Wang JL, Ko WJ, Lee PH, Chou NK, Wang SS, et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Am J Med Sci 2007;334: 106-110.
22. D'Albuquerque LA, Gonzalez AM, Filho HL, Copstein JL, Larrea FI, Mansero JM, et al. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant 2007;7:680-684.
23. Jung H, Oh YM, Lee SD, Kim WS, Kim DS, Kim WD, et al. Clinical characteristics of tuberculosis in liver or heart transplant recipients. Tuberc Respir Dis 2006;61:440-446.
24. Berzigotti A, Bianchi G, Dapporto S, Pinna AD, Zoli M. Isolated hepatic tuberculoma after orthotopic liver transplantation: a case report. Intern Emerg Med 2006;1:314-316.
25. Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, De Ruvo N, Meacci M, et al. Posttransplant Mycobacterium tuberculosis disease following liver transplantation and the need for cautious evaluation of quantiferon TB GOLD results in the transplant setting: a case report. Transplant Proc 2006;38:1083-1085.
26. Kamiya H, Toyota E, Kobayashi N, Kudo K. A case of pulmonary tuberculosis complicated with an orthotopic liver transplantation [in Japanese]. Kekkaku 2006;81: 351-355.
27. Agildere AM, Basaran C, Cakir B, Ozgul E, Kural F, Haberal M. Evaluation of neurologic complications by brain MRI in kidney and liver transplant recipients. Transplant Proc 2006;38:611-618.
28. Surjan RCT, Bonazzi PR, Sepulveda A, Oliveira AC, Bacchella T, Machado MCC, Abdala E. Tuberculosis in liver transplant recipients [abstract]. World Transplant Congress 2006 Poster Abstracts. American Journal of Transplantation 2006: 6 Suppl 2: 965-966.
29. Spearman CW, McCulloch M, Millar AJ, Burger H, Numanoglu A, Goddard E, et al. Liver transplantation at Red Cross War Memorial Children's Hospital. SAMJ 2006;96: 960-963.
30. Spearman CW, McCulloch M, Millar AJ, Burger H, Numanoglu A, Goddard E, et al. Liver transplantation for children: Red Cross children's hospital experience. Transplant Proc 2005;37:1134-1137.
31. Goddard EA, Spearman CWN, McCulloch M, Burger HH, Numanoglu A, Miller AJW, Kahn D, Ireland JD. Tuberculosis in paediatric liver transplant recipients in the developing world [abstract]. Pediatr Transplant 2005;9: 85. Abstract 169.
32. Millar AJ, Spearman W, McCulloch M, Goddard E, Raad J, Rode H, et al. Liver transplantation for children-the Red Cross Children's Hospital experience. Pediatr Transplant 2004;8:136-144.
33. Botha JF, Spearman CW, Millar AJ, Michell L, Gordon P, Lopez T, et al. Ten years of liver transplantation at Groote Schuur Hospital. SAMJ 2000;90:880-883.
34. Millar AJ, Spearman CW, McCulloch M, Goddard E, Lopez T, Thomas J, et al. Liver transplantation in children - the Red Cross War Memorial Children's Hospital experience. S Afr J Surg 2000;38:91-97.
35. Chee CB, Wang YT. Tuberculosis: public health aspects. Re: Tuberculosis post-liver transplantation: a rare but complicated disease. Ann Acad Med Singapore 2005;34: 405; author reply 406.
36. Akamatsu N, Sugawara Y, Nakajima J, Kishi Y, Niiya T, Kaneko J, Makuuchi M. Resection of a pulmonary lesion after liver transplantation: report of a case. Surg Today 2005;35:976-978.
37. Alothman A, Al Abdulkareem A, Al Hemsi B, Issa S, Al Sarraj I, Masoud F. Isolated hepatic tuberculosis in a transplanted liver. Transpl Infect Dis 2004;6:84-86.
38. Cillo U, Bassanello M, Vitale A, D'Antiga L, Zanus G, Brolese A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. Transpl Int 2005;17:713-716.
39. Kim S, Kim Y, Sohn J, Kang M. Four cases of Mycobacterium tuberculosis infections in liver transplant recipients in Korea [abstract]. Clin Microbiol Infect 2004; 10(suppl 3):664. Abstract R2313.
40. Torre-Cisneros J, Castoén JJ, Moreno J, Rivero A, Vidal E, Jurado R, Kindelán JM. Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. Transplantation 2004; 77:1376-1380.
41. Torre-Cisneros J, de la Mata M, Rufian S, Villanueva Marcos JL, Gutierrez Aroca J, Casal M, et al. Importance of surveillance mycobacterial cultures after liver transplantation. Abstr Intersci Conf Antimicrob Agents Chemother 1995;35:342.
42. Henderson C, Meyers B, Gultekin SH, Liu B, Zhang DY. Intracranial tuberculoma in a liver transplant patient: first reported case and review of the literature. Am J Transplant 2003;3:88-93.
43. Al-Moamary MS, Al-Baz S, Alothman A, Memish Z, Al-Jahdali H, Al-Abdulkareem A. Does tuberculin skin test predict tuberculosis in patients with end-stage liver disease? Saudi Med J 2003;24:1269-1270.
44. Al-Moamary MS, Al-Baz S, Alothman A, Memish Z, Al-Abdulkareem A. The value of tuberculin skin test in endstage liver disease. Chest 2000;118(suppl):267S.
45. Benito N, Garcia E, Horcajada JP, Martinez JA, Onzalez J, Oppenheimer F, et al. Case-control study of tuberculosis (TB) in transplant recipients (TR) versus general population (GP). Abstr Intersci Conf Antimicrob Agents Chemother 2001;41:480-481.
46. Benito N, Sued O, Moreno A, Gonzalez J, Navasa M, Rimola A. Tuberculosis prophylaxis in liver transplant recipients. Abstr Intersci Conf Antimicrob Agents Chemother 2000;40:457.
47. Cavusoglu C, Cicek-Saydam C, Karasu Z, Karaca Y, Ozkahya M, Toz H, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant 2002;16:257-261.
48. Fulya G, Yaman T, Funda Y, Zeki K, Murat A, Ahmet M, Cengiz C. Disseminated tuberculosis with massive gastrointestinal bleeding after liver transplantation. Turk J Gastroenterol 2000;2:334-337.
49. Graham JC, Kearns AM, Magee JG, El-Sheikh MF, Hudson M, Manas D, et al. Tuberculosis transmitted through transplantation. J Infect 2001;43:251-254.
50. Meyers B. Mycobacterium tuberculosis infection in solid organ transplant recipients. Clin Infect Dis 2005;41:410.
51. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000;69:64-69.
52. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994;58:301-306.
53. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E. Increased incidence of tuberculosis in orthotopic liver transplant (OLT) patients: clinical aspects/strategies for prevention and treatment. Abstr Intersci Conf Antimicrob Agents Chemother 1994;34:197.
54. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients-incidence, timing, and longterm follow-up. Clin Transplant 2000;14:1-7.
55. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996;63:364-369.
56. Kahn D, Spearman CW, Millar AJ. History of liver transplantation at the University of Cape Town and Groote Schuur Hospital. S Afr J Surg 2000;38:88-90.
57. Verma A, Dhawan A, Wade JJ, Lim WH, Ruiz G, Price JF, et al. Mycobacterium tuberculosis infection in pediatric liver transplant recipients. Pediatr Infect Dis J 2000;19: 625-630.
58. Verma A, Lim WH, Dhawan A, Baker AJ, Hadzic N, Ruiz G, Wade I, Price JF, Rela M, Heaton ND. Mycobacterium tuberculosis infection in paediatric liver transplant recipients [abstract]. Hepatology 1999;30(pt 2):667A.
59. D'Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, Mieli-Vergani G. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73:80-84.
60. Revald P, Olsen BS, Gronbaek H, Duel P. Intramedullary tuberculous abscess in a patient with liver transplantation [in Danish]. Ugeskr Laeger 2000;162:502-503.
61. Chaparro S, Montoya J, Keeffe E, Rhee J, Small P. Risk of tuberculosis in tuberculin-positive liver transplant patients. Tuber Lung Disease 2000;80:97-98.
62. Chaparro SV, Montoya JG, Keeffe EB, Rhee JT, Small PM. Risk of tuberculosis in tuberculin skin test-positive liver transplant patients. Clin Infect Dis 1999;29:207-208.
63. Coelho JCU, Wiederkehr JC, Parolin MB, Balbi E, Nassif AE. Isolated tuberculosis of the pancreas after orthotopic liver transplantation. Liver Transpl Surg 1999;5:153-155.
64. Lalonde RG, Barkun J. Prolonged ciprofloxacin therapy fails to prevent reactivation tuberculosis. Clin Infect Dis 1998;27:913-914.
65. Quereda Navarro DC, Navas Elorza E, Lopez San Roman A, Moreno Caparros A. Febrile syndrome and adrenal lesion in a patient receiving a hepatic transplant [in Spanish]. Rev Clin Esp 1998;198:690-700.
66. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997;63: 1278-1286.
67. Aguado JM, Gavalda J, Torre-Cisneros J, Blanes M, Carvatala J, Moreno A, Munoz P, Gurgui M, Lumbreras C. Incidence, risk factors and outcome from tuberculosis in solid organ transplantation: a case-control study. Abstr Intersci Conf Antimicrob Agents Chemother 1997;37:206.
68. Folgueira L, Delgado R, Palenque E, Aguado JM, Noriega AR. Rapid diagnosis of Mycobacterium tuberculosis bacteremia by PCR. J Clin Microbiol 1996;34:512-515.
69. Aguado JM, Hayek M, Palenque E, Lumbreras C, Lizasoain M, Noriega AR. Tuberculosis (TB) in solid organ transplantation (SOT): an increasing problem with serious clinical consequences [abstract]. Abstr Intersci Conf Antimicrob Agents Chemother 1994;34:107. Abstract J116.
70. Kiuchi T. Liver transplantation and tuberculosis [in Japanese]. Kekkaku 2000;75:685-690.
71. Kiuchi T, Inomata Y, Uemoto S, Satomura K, Egawa H, Okajima H, et al. A hepatic graft tuberculosis transmitted from a living-related donor. Transplantation 1997; 63:905-907.
72. Kiuchi T, Tanaka K, Inomata Y, Uemoto S, Satomura K, Egawa H, et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc 1996;28:3171-3172.
73. Willemart T, Godfraind C, Pieters A, Lerut J, Laterre C. Cerebellar tuberculous abscess in a liver transplant patient. Acta Neurol Belg 1997;97:55-55.
74. Nishizaki T, Yanaga K, Soejima Y, Kishikawa K, Kajiyama K, Uchiyama H, et al. Tuberculosis following liver transplantation: report of a case and review of the literature. Transpl Int 1996;9:589-592.
75. Chusid MJ, Splaingard ML, Tweddell JS, Rice TR, Adams M, Havens PL, Kehl KS. Pulmonary tuberculosis after lung-liver transplantation for cystic fibrosis. Pediatr Infect Dis J 1996;15:462-464.
76. Wada S, Kusne S, Fung J, Rakela J. Foreign born is the most important risk factor for tuberculosis infection in adult liver transplant recipients. Abstr Intersci Conf Antimicrob Agents Chemother 1996;36:195.
77. Kusne S, Irish W, Geary K, Ondick L, Rakela J, Fung J. Anergy panel and purified protein derivative (PPD) skin testing are poor tuberculosis (TB) screening method in adult liver transplant candidates. Abstr Intersci Conf Antimicrob Agents Chemother 1995;35:262.
78. Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Clin Infect Dis 1997;25:486.
79. Ferrell LD, Lee R, Brixko C, Bass NM, Lake JR, Roberts JP, et al. Hepatic granulomas following liver transplantation. Transplantation 1995;60:926-933.
80. Sokal EM, Silva ES, Hermans D, Reding R, de Ville de Goyet J, Buts JP, Otte JB. Orthotopic liver transplantation for Crigler-Najjar type I disease in six children. Transplantation 1995;60:1095-1098.
81. Stöblen F, Neuhaus R, Neumann K, Grauhan O, Bechstein WO, Klein E, et al. Tuberculosis in liver transplant recipients: recurrence after transplantation? Transplant Proc 1994;26:3604-3605.
82. Stoblen F, Blumhard G, Kaisers U, Raakow R, Bechstein W, Neuhaus P. Outcome of severe pneumonias after orthotopic liver transplantation. Transplant Proc 1994;26: 3681-3682.
83. McDiarmid SV, Blumberg DA, Remotti H, Vargas J, Tipton JR, Ament ME, Busuttil RW. Mycobacterial infections after pediatric liver transplantation: a report of three cases and review of the literature. J Pediatr Gastroenterol Nutr 1995;20:425-431.
84. Ascher N, Lake J, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20(pt 2):24S-27S.
85. Salizzoni JL, Tiruviluamala P, Reichman LB. Liver transplantation: an unheralded probable risk for tuberculosis. Tuber Lung Dis 1992;73:232-238.
86. Sterneck M, Ferrell L, Ascher N, Roberts J, Lake J. Mycobacterial infection after liver transplantation: a report of three cases and review of the literature. Clin Transplant 1992;6:55-61.
87. Vajro P, Vegnente A, Devincenzo A, Lorio R, Fontanella A, Guida S, Tedesco M. Follow-up of 25 children who underwent liver transplantation [in Italian]. Ital J Pediatr 1992;18:44-49.
88. Lie TS, Hofer M. Tuberculosis following liver transplantation [in German]. Dtsch Med Wochenschr 1988;113: 731-734.
89. Lie TS, Hofer M, Hohnke C. Successful treatment of tuberculosis after liver transplantation. Langenbecks Arch Chir 1987;372:893-894.
90. Piza F, Funovics J, Muhlbacher F. Lebertransplantation-indikation und postoperativer verlauf. Wien Klin Wochenschr 1986;98:838-842.
91. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007;83:1557-1562.
92. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid (INH) chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Abstr Intersci Conf Antimicrob Agents Chemother 2002;42:350-351.
93. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002;74:892-895.
94. Dursuin P, Ersoz S, Gultekin M, Aksan G, Yuce K, Ayhan A. Disseminated peritoneal tuberculosis mimicking advanced-stage endodermal sinus tumor: a case report. Int J Gynecol Cancer 2006;16:303-307.
95. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl 2006;12:1427-1430.
96. Barcena R, Oton E, Angeles Moreno M, Fortué n J, Garcia-Gonzalez M, Moreno A, de Vicente E. Is liver transplantation advisable for isoniazid fulminant hepatitis in activeextrapulmonarytuberculosis? Am J Transplant 2005;5: 2796-2798.
97. Tost JR, Vidal R, Caylà J, Díaz-Cabanela D, Jiménez A, Broquetas JM. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005;9: 534-540.
98. Lee DS, Woo JG, Lee HH, Lee KW, Joh JW, Kim SJ, et al. Auxiliary partial orthotopic liver transplantation in the treatment of acute liver failure: a case report. Transplant Proc 2004;36:2228-2229.
99. Marra F, Cox VC, Fitzgerald JM, Moadebi S, Elwood RK. Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant. Int J Tuberc Lung Dis 2004;8:905-909.
100. Kunimoto D, Warman A, Beckon A, Doering D, Melenka L. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis 2003;36:E158-E161.
101. Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, et al. Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J Surg 2002;25: 277-284.
102. Girotto L, Gjonovich A, Preciso G. Fulminant liver failure caused by antitubercular drugs. Report of a clinical case [in Italian]. Minerva Anestesiol 2000;66:249-251.
103. Mizoe A, Fujioka H, Kamohara Y, Watanabe Y, Azuma T, Kanematsu T. The significance of measuring the serum total bile acids levels during orthotopic liver transplantation. Hepatogastroenterology 1999;46:2454-2459.
104. Turner MO, Elwood RK. Severe hepatic complications of antituberculous therapy. Can J Infect Dis 1999;10:167-169.
105. Ibarguen SE, Sharp HL. Liver failure in post-hepatitis A following 5 months of prophylactic isoniazid. Clin Pediatr 1989;28:75.
106. Moitinho E, Salmeron JM, Mas A, Bruguera M, Rodes J. Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence [in Spanish]. Gastroenterol Hepatol 1996;19:448-451.
107. Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994;39: 2255-2259.
108. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Miller C, Schwartz M, Mor E. Acute hepatic failure in seven patients after prophylaxis and therapy with antituberculous agents: successful treatment with orthotopic liver transplantation. Transplantation 1994;58:372-377.
109. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
110. Nagai S, Fujimoto Y, Taira K, Egawa H, Takada Y, Kiuchi T, Tanaka K. Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis. Clin Transplant 2007;21:229-234.
111. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001;33(suppl 1):S15-S21.
112. Chugh KS, Jha V. Tuberculosis in organ transplant recipients. Transplant Proc 2003;35:2676-2677.
113. Wu SS, Chao CS, Vargas JH, Sharp HL, Martín MG, McDiarmid SV, et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2000;84:173-179.
114. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-1018.
115. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996; 164:486-491.
116. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145(pt 1):494-497.
117. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection. A 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-123.
118. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994;57:1684-1684.
119. Agarwal SK, Gupta S, Dasg SC, Bhowmik D, Tiwari SC. Prospective randomized trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol 2004;36: 425-431.
120. Skogberg K, Ruutu P, Tukianinen P, Valtonen V. Effect of immunosuppressive therapy on the clinical presentation and outcome of tuberculosis. Clin Infect Dis 1993;17: 1012-1017.
121. Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med 1987;107:837-842.
122. Centers for Disease Control and Prevention. Trends in tuberculosis incidence-United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:245-250.
123. Mycobacterium tuberculosis. AmJ Transplant 2004;4:37-41.
124. Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002;287:991-995.
125. Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995;333:222-227.
126. Ehrenkranz NH, Kicklighter JL. Tuberculosis outbreak in a general hospital: evidence for airborne spread of infection. Ann Intern Med 1977;77:377-382.
127. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49(RR-6): 1-51.
128. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
129. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-587.
130. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-370.
131. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-1227.
132. Gajda A, Ellert-Zygadlowska J, Halota W. Tuberculin reactions in patients with acute viral hepatitis [in Polish]. Przegl Lek 1978;35:287-289.
133. Pak FP. Dynamics of tuberculin reaction in patients with pulmonary tuberculosis who acquired epidemic hepatitis [in Polish]. Probl Tuberk 1966;44:43-48.
134. Sciaccaluga M. Measurement of intradermic reaction to PPD in chronic hepatitis and cirrhosis [in Italian]. Minerva Med 1975;66:1295-1299.
135. Larke RPB, Harley DD, Enarson DA. Relationship between tuberculin reactivity and hepatitis B virus infection in the Northwest territories. Artic Med Res 1991(suppl):371-373.
136. Hisada M, Shima T, Okayama A, Mueller N, Tsubouchi H, Stuver S. Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV-I carriers in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:421-425.
137. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971;285: 1506-1509.
138. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis 1993;17:968-975.
139. Snider DE. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 1985;253:3438-3439.
140. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-354.
141. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-2801.
142. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-294.
143. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003;98:167-174.
144. Tocque K, Bellis MA, Beeching NJ, Syed Q, Remmington T, Davies PD. A case-control study of lifestyle risk factors associated with tuberculosis in Liverpool, North-West England. Eur Respir J 2001;18:959-964.
145. Buskin SE, Gale JL, Weiss NS, Nolan CM. Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990. Am J Public Health 1994;84:1750-1756.